SG11201704717VA - 1,3-thiazol-2-yl substituted benzamides - Google Patents

1,3-thiazol-2-yl substituted benzamides

Info

Publication number: SG11201704717VA
Authority: SG; Singapore
Prior art keywords: thiazol; substituted benzamides; benzamides; substituted
Prior art date: 2014-12-09

Application number

SG11201704717VA

Inventor

Adam James Davenport

Nico Braeuer

Oliver Martin Fischer

Andrea Rotgeri

Antje Rottmann

Ioana Neagoe

Jens Nagel

Anne-Marie Godinho-Coelho

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-09

Filing date

2015-12-07

Publication date

2017-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52015966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201704717V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-07 Application filed by Bayer Ag filed Critical Bayer Ag

2017-08-30 Publication of SG11201704717VA publication Critical patent/SG11201704717VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

SG11201704717VA 2014-12-09 2015-12-07 1,3-thiazol-2-yl substituted benzamides SG11201704717VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14196954		2014-12-09
PCT/EP2015/078765 WO2016091776A1 (en)	2014-12-09	2015-12-07	1,3-thiazol-2-yl substituted benzamides

Publications (1)

Publication Number	Publication Date
SG11201704717VA true SG11201704717VA (en)	2017-08-30

Family

ID=52015966

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10202012274RA SG10202012274RA (en)	2014-12-09	2015-12-07	1,3-thiazol-2-yl substituted benzamides
SG11201704717VA SG11201704717VA (en)	2014-12-09	2015-12-07	1,3-thiazol-2-yl substituted benzamides

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10202012274RA SG10202012274RA (en)	2014-12-09	2015-12-07	1,3-thiazol-2-yl substituted benzamides

Country Status (42)

Country	Link
US (5)	US10174016B2 (en)
EP (2)	EP3230281B1 (en)
JP (2)	JP6544665B2 (en)
KR (2)	KR20230098368A (en)
CN (2)	CN110256418B (en)
AR (2)	AR102948A1 (en)
AU (1)	AU2015359626B2 (en)
BR (1)	BR112017012327B1 (en)
CA (1)	CA2969952A1 (en)
CL (1)	CL2017001488A1 (en)
CO (1)	CO2017005742A2 (en)
CR (2)	CR20210108A (en)
CU (1)	CU24411B1 (en)
CY (2)	CY1124486T1 (en)
DK (2)	DK3587417T3 (en)
DO (2)	DOP2017000137A (en)
EA (2)	EA034273B1 (en)
EC (1)	ECSP17036253A (en)
ES (2)	ES2882952T3 (en)
HR (2)	HRP20211002T1 (en)
HU (2)	HUE055290T2 (en)
IL (6)	IL252665B (en)
JO (1)	JOP20150301B1 (en)
LT (2)	LT3587417T (en)
MA (2)	MA50674B1 (en)
MX (2)	MX387478B (en)
MY (1)	MY192690A (en)
NI (1)	NI201700073A (en)
NZ (1)	NZ761161A (en)
PE (2)	PE20220253A1 (en)
PH (1)	PH12017501079A1 (en)
PL (2)	PL3587417T3 (en)
PT (2)	PT3587417T (en)
RS (2)	RS63014B1 (en)
SG (2)	SG10202012274RA (en)
SI (2)	SI3230281T1 (en)
SV (1)	SV2017005461A (en)
TN (1)	TN2017000244A1 (en)
TW (2)	TWI716371B (en)
UA (1)	UA120382C2 (en)
UY (1)	UY36422A (en)
WO (1)	WO2016091776A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110256418B (en)	2014-12-09	2023-01-20	拜耳公司	1, 3-thiazol-2-yl substituted benzamides
TWI794171B (en)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Combination therapies of hdac inhibitors and pd-1 inhibitors
CN106588785A (en) *	2016-12-02	2017-04-26	山东吉田香料股份有限公司	Preparation method of acetylpyrazine
US10111883B1 (en) *	2017-09-18	2018-10-30	Bellus Health Cough Inc.	Selective P2X3 modulators
HU231206B1 (en)	2017-12-15	2021-10-28	Richter Gedeon Nyrt.	Triazolobenzazepines
CA3100096A1 (en) *	2018-05-15	2019-11-21	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EA202092678A1 (en)	2018-05-15	2021-04-12	Байер Акциенгезельшафт	1,3-THIAZOL-2-YL-SUBSTITUTED BENZAMIDES FOR TREATMENT OF DISEASES ASSOCIATED WITH SENSITIZATION OF NERVOUS FIBERS
EP3862000B1 (en)	2018-10-05	2023-10-18	Shionogi & Co., Ltd	Medicine for treating chronic cough
US20210346391A1 (en) *	2018-10-10	2021-11-11	Bellus Health Cough Inc.	Treatment of pruritus with p2x3 modulators
WO2020174283A1 (en) *	2019-02-25	2020-09-03	Bellus Health Cough Inc.	Treatment with p2x3 modulators
MX2021012162A (en) *	2019-04-05	2021-11-03	Syngenta Crop Protection Ag	Pesticidally active diazine-amide compounds.
CA3131861A1 (en) *	2019-04-11	2020-10-15	Jurgen Harry Schaetzer	Pesticidally active diazine-amide compounds
JP2022534434A (en)	2019-05-31	2022-07-29	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	Pyridopyrimidine derivatives as P2X3 inhibitors
PH12021552881A1 (en)	2019-05-31	2022-07-25	Chiesi Farm Spa	Amino quinazoline derivatives as p2x3 inhibitors
EP3757103A1 (en)	2019-06-27	2020-12-30	Bayer AG	Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN113082023B (en) *	2019-12-23	2024-03-01	武汉朗来科技发展有限公司	Pharmaceutical combination of P2X3 inhibitor and P2X4 inhibitor and application thereof
WO2021238834A1 (en) *	2020-05-25	2021-12-02	中国医药研究开发中心有限公司	Arylformamide compound and preparation method and medical use thereof
WO2022063205A1 (en) *	2020-09-24	2022-03-31	中国医药研究开发中心有限公司	Aryl formamide compound, preparation method for same, and medicinal uses thereof
IL301667A (en) *	2020-09-30	2023-05-01	Humanwell Healthcare Group Co Ltd	Benzamide compound and its use
KR20230113309A (en)	2020-11-27	2023-07-28	키에시 파르마슈티시 엣스. 피. 에이.	Aminoquinazoline Derivatives as P2X3 Inhibitors
CA3196335A1 (en)	2020-11-27	2022-06-02	Chiesi Farmaceutici S.P.A.	Phthalazine derivatives as p2x3 inhibitors
US20230416233A1 (en)	2020-11-27	2023-12-28	Chiesi Farmaceutici S.P.A.	(aza)quinoline 4-amines derivatives as p2x3 inhibitors
WO2022253943A1 (en)	2021-06-04	2022-12-08	Bayer Aktiengesellschaft	Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide
WO2022253945A1 (en)	2021-06-04	2022-12-08	Bayer Aktiengesellschaft	Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
US12024285B1 (en)	2022-03-10	2024-07-02	Skypad Tech, Inc.	Modular mobility system including thrusters movably connected to a support structure
JP2025510348A (en)	2022-03-29	2025-04-14	人福医薬集団股▲分▼公司	P2X3 inhibitor compounds and their salts, crystal polymorphs and uses
WO2024131948A1 (en) *	2022-12-22	2024-06-27	人福医药集团股份公司	Method for preparing p2x3 inhibitor
WO2024240728A1 (en)	2023-05-22	2024-11-28	Chiesi Farmaceutici S.P.A.	Process and intermediates for the preparation of a p2x3 inhibitor
CN117777048B (en) *	2023-09-25	2024-09-20	上海科利生物医药有限公司	Preparation method of chiral 2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2606760C (en)	2005-05-04	2014-12-23	Renovis, Inc.	Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
JP5021734B2 (en)	2006-06-29	2012-09-12	エフ．ホフマン−ラロシュアーゲー	Tetrazole substituted arylamide
US8501933B2 (en) *	2006-11-09	2013-08-06	Roche Palo Alto Llc	Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
KR101165936B1 (en)	2006-11-09	2012-07-19	에프. 호프만-라 로슈 아게	Thiazole and oxazole-substituted arylamides
US8653091B2 (en)	2007-04-02	2014-02-18	Evotec Ag	Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
EP2139334B1 (en)	2007-04-17	2013-07-03	Evotec AG	2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
US20090099195A1 (en)	2007-05-08	2009-04-16	Astrazeneca Ab	Therapeutic Compounds 570
TW200906826A (en) *	2007-06-12	2009-02-16	Genelabs Tech Inc	Anti-viral inhibitors and methods of use
EP2215049B1 (en)	2007-10-31	2019-06-12	Merck Sharp & Dohme Corp.	P2x3, receptor antagonists for treatment of pain
WO2009058299A1 (en)	2007-10-31	2009-05-07	Merck & Co., Inc.	P2x3 receptor antagonists for treatment of pain
PL2234976T3 (en)	2007-12-17	2013-09-30	Hoffmann La Roche	Novel pyrazole-substituted arylamides
EP2234981B1 (en)	2007-12-17	2016-03-30	F. Hoffmann-La Roche AG	Novel imidazole-substituted arylamides
BRPI0821266B8 (en)	2007-12-17	2023-02-07	Hoffmann La Roche	TRIAZOL- SUBSTITUTED ARILAMIDE DERIVATIVES AND THEIR USE AND PHARMACEUTICAL COMPOSITION
AU2008337665B2 (en)	2007-12-17	2014-01-16	F. Hoffmann-La Roche Ag	Tetrazole-substituted arylamide derivatives and their use as P2x3 and/or P2x2/3 purinergic receptor antagonists
CA2715835C (en)	2008-02-29	2017-03-21	Renovis, Inc.	Amide compounds, compositions and uses thereof
US20110237578A1 (en)	2008-09-18	2011-09-29	Zhi-Liang Wei	Amide compounds, compositions and uses thereof
ES2534199T3 (en)	2008-10-31	2015-04-20	Merck Sharp & Dohme Corp.	P2X3 receptor antagonists for pain management
WO2010069794A1 (en)	2008-12-16	2010-06-24	F. Hoffmann-La Roche Ag	Thiadiazole-substituted arylamides
SG177308A1 (en)	2009-06-22	2012-02-28	Hoffmann La Roche	Novel biphenyl and phenyl-pyridine amides
ES2593405T3 (en)	2009-06-22	2016-12-09	F. Hoffmann-La Roche Ag	New arylamides substituted by benzoxazolone
US8901156B2 (en)	2010-01-13	2014-12-02	Tempero Pharmaceuticals, Inc.	Compounds and methods
WO2013009810A1 (en)	2011-07-13	2013-01-17	Tempero Pharmaceuticals, Inc.	Methods of treatment
US9562041B2 (en) *	2012-05-16	2017-02-07	Glaxosmithkline Llc	Enhancer of zeste homolog 2 inhibitors
EP2900653A1 (en)	2012-09-28	2015-08-05	Pfizer Inc.	Benzamide and heterobenzamide compounds
EP3998267A1 (en)	2013-01-31	2022-05-18	Bellus Health Cough Inc.	Imidazopyridine compounds and uses thereof
CN110256418B (en) *	2014-12-09	2023-01-20	拜耳公司	1, 3-thiazol-2-yl substituted benzamides
US10183937B2 (en) *	2014-12-09	2019-01-22	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides
CA3100096A1 (en)	2018-05-15	2019-11-21	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EA202092678A1 (en)	2018-05-15	2021-04-12	Байер Акциенгезельшафт	1,3-THIAZOL-2-YL-SUBSTITUTED BENZAMIDES FOR TREATMENT OF DISEASES ASSOCIATED WITH SENSITIZATION OF NERVOUS FIBERS
EP3757103A1 (en)	2019-06-27	2020-12-30	Bayer AG	Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases

2015
- 2015-12-07 CN CN201910653985.0A patent/CN110256418B/en not_active Expired - Fee Related
- 2015-12-07 PE PE2021001723A patent/PE20220253A1/en unknown
- 2015-12-07 RS RS20220250A patent/RS63014B1/en unknown
- 2015-12-07 SG SG10202012274RA patent/SG10202012274RA/en unknown
- 2015-12-07 EP EP15804824.9A patent/EP3230281B1/en active Active
- 2015-12-07 SI SI201531643T patent/SI3230281T1/en unknown
- 2015-12-07 ES ES15804824T patent/ES2882952T3/en active Active
- 2015-12-07 US US15/534,855 patent/US10174016B2/en active Active
- 2015-12-07 UY UY0001036422A patent/UY36422A/en active IP Right Grant
- 2015-12-07 AU AU2015359626A patent/AU2015359626B2/en not_active Ceased
- 2015-12-07 PL PL19181710T patent/PL3587417T3/en unknown
- 2015-12-07 WO PCT/EP2015/078765 patent/WO2016091776A1/en active Application Filing
- 2015-12-07 MA MA50674A patent/MA50674B1/en unknown
- 2015-12-07 LT LTEP19181710.5T patent/LT3587417T/en unknown
- 2015-12-07 MY MYPI2017702127A patent/MY192690A/en unknown
- 2015-12-07 UA UAA201707107A patent/UA120382C2/en unknown
- 2015-12-07 MX MX2020005909A patent/MX387478B/en unknown
- 2015-12-07 SG SG11201704717VA patent/SG11201704717VA/en unknown
- 2015-12-07 EA EA201891120A patent/EA034273B1/en not_active IP Right Cessation
- 2015-12-07 MX MX2017007658A patent/MX377651B/en active IP Right Grant
- 2015-12-07 EA EA201791261A patent/EA032312B1/en not_active IP Right Cessation
- 2015-12-07 PE PE2017000984A patent/PE20180227A1/en unknown
- 2015-12-07 CN CN201580075714.1A patent/CN107207507B/en not_active Expired - Fee Related
- 2015-12-07 PT PT191817105T patent/PT3587417T/en unknown
- 2015-12-07 NZ NZ761161A patent/NZ761161A/en unknown
- 2015-12-07 HU HUE15804824A patent/HUE055290T2/en unknown
- 2015-12-07 MA MA41135A patent/MA41135B1/en unknown
- 2015-12-07 JO JOP/2015/0301A patent/JOP20150301B1/en active
- 2015-12-07 DK DK19181710.5T patent/DK3587417T3/en active
- 2015-12-07 CR CR20210108A patent/CR20210108A/en unknown
- 2015-12-07 KR KR1020237021217A patent/KR20230098368A/en active Pending
- 2015-12-07 PT PT158048249T patent/PT3230281T/en unknown
- 2015-12-07 ES ES19181710T patent/ES2908822T3/en active Active
- 2015-12-07 JP JP2017530625A patent/JP6544665B2/en not_active Expired - Fee Related
- 2015-12-07 KR KR1020177018575A patent/KR102548799B1/en active Active
- 2015-12-07 LT LTEP15804824.9T patent/LT3230281T/en unknown
- 2015-12-07 CA CA2969952A patent/CA2969952A1/en active Pending
- 2015-12-07 RS RS20211014A patent/RS62227B1/en unknown
- 2015-12-07 TN TN2017000244A patent/TN2017000244A1/en unknown
- 2015-12-07 DK DK15804824.9T patent/DK3230281T3/en active
- 2015-12-07 HU HUE19181710A patent/HUE058009T2/en unknown
- 2015-12-07 HR HRP20211002TT patent/HRP20211002T1/en unknown
- 2015-12-07 EP EP19181710.5A patent/EP3587417B9/en active Active
- 2015-12-07 HR HRP20220371TT patent/HRP20220371T1/en unknown
- 2015-12-07 SI SI201531781T patent/SI3587417T1/en unknown
- 2015-12-07 CR CR20170242A patent/CR20170242A/en unknown
- 2015-12-07 CU CU2017000077A patent/CU24411B1/en unknown
- 2015-12-07 BR BR112017012327-4A patent/BR112017012327B1/en not_active IP Right Cessation
- 2015-12-07 PL PL15804824T patent/PL3230281T3/en unknown
- 2015-12-08 TW TW104141168A patent/TWI716371B/en not_active IP Right Cessation
- 2015-12-08 TW TW110100512A patent/TWI780562B/en not_active IP Right Cessation
- 2015-12-09 AR ARP150104007A patent/AR102948A1/en unknown
2017
- 2017-06-05 IL IL25266517A patent/IL252665B/en active IP Right Grant
- 2017-06-08 PH PH12017501079A patent/PH12017501079A1/en unknown
- 2017-06-09 CO CONC2017/0005742A patent/CO2017005742A2/en unknown
- 2017-06-09 DO DO2017000137A patent/DOP2017000137A/en unknown
- 2017-06-09 EC ECIEPI201736253A patent/ECSP17036253A/en unknown
- 2017-06-09 NI NI201700073A patent/NI201700073A/en unknown
- 2017-06-09 SV SV2017005461A patent/SV2017005461A/en unknown
- 2017-06-09 CL CL2017001488A patent/CL2017001488A1/en unknown
- 2017-11-21 US US15/820,429 patent/US10202369B2/en active Active
2018
- 2018-08-08 DO DO2018000182A patent/DOP2018000182A/en unknown
- 2018-11-13 JP JP2018212898A patent/JP6647371B2/en not_active Expired - Fee Related
- 2018-11-15 US US16/192,314 patent/US10472354B2/en active Active
2019
- 2019-09-19 IL IL269467A patent/IL269467B/en active IP Right Grant
- 2019-09-19 IL IL269468A patent/IL269468B/en active IP Right Grant
- 2019-09-25 IL IL269661A patent/IL269661B/en active IP Right Grant
- 2019-10-01 US US16/589,838 patent/US11142523B2/en active Active
2020
- 2020-06-07 IL IL275183A patent/IL275183B/en active IP Right Grant
- 2020-08-13 AR ARP200102296A patent/AR119761A2/en not_active Application Discontinuation
2021
- 2021-06-14 IL IL283979A patent/IL283979B/en unknown
- 2021-08-20 CY CY20211100750T patent/CY1124486T1/en unknown
- 2021-09-09 US US17/470,459 patent/US20230053411A1/en not_active Abandoned
2022
- 2022-03-15 CY CY20221100217T patent/CY1125083T1/en unknown

Also Published As

Publication number	Publication date
US10202369B2 (en)	2019-02-12
JP6544665B2 (en)	2019-07-17
RS63014B1 (en)	2022-04-29
ECSP17036253A (en)	2017-06-30
EP3230281A1 (en)	2017-10-18
CU20170077A7 (en)	2017-11-07
PT3587417T (en)	2022-03-16
DK3230281T3 (en)	2021-08-16
TW202130637A (en)	2021-08-16
MX377651B (en)	2025-03-11
MX2017007658A (en)	2018-08-01
AU2015359626A1 (en)	2017-06-29
JP6647371B2 (en)	2020-02-14
CR20170242A (en)	2018-02-02
DOP2018000182A (en)	2018-09-15
BR112017012327B1 (en)	2023-04-11
HUE055290T2 (en)	2021-11-29
CR20210108A (en)	2021-04-27
TWI716371B (en)	2021-01-21
US20200131169A1 (en)	2020-04-30
JP2017537122A (en)	2017-12-14
US20180093980A1 (en)	2018-04-05
MX387478B (en)	2025-03-18
CO2017005742A2 (en)	2017-09-20
MA41135B1 (en)	2021-10-29
PT3230281T (en)	2021-08-19
IL252665B (en)	2019-10-31
IL269661B (en)	2020-07-30
AR102948A1 (en)	2017-04-05
CN107207507A (en)	2017-09-26
TW201629053A (en)	2016-08-16
MX2020005909A (en)	2021-10-28
UA120382C2 (en)	2019-11-25
EP3587417B1 (en)	2022-01-05
IL269468A (en)	2019-11-28
DOP2017000137A (en)	2017-07-31
WO2016091776A1 (en)	2016-06-16
ES2882952T3 (en)	2021-12-03
BR112017012327A2 (en)	2018-02-27
BR112017012327A8 (en)	2021-02-23
IL269661A (en)	2019-11-28
IL269467B (en)	2020-08-31
IL269468B (en)	2020-06-30
IL275183A (en)	2020-07-30
KR20230098368A (en)	2023-07-03
CA2969952A1 (en)	2016-06-16
MY192690A (en)	2022-09-01
RS62227B1 (en)	2021-09-30
AR119761A2 (en)	2022-01-12
MA50674A (en)	2021-03-31
PE20220253A1 (en)	2022-02-16
EA032312B1 (en)	2019-05-31
KR102548799B1 (en)	2023-06-27
EA201891120A1 (en)	2018-10-31
LT3587417T (en)	2022-02-10
DK3587417T3 (en)	2022-03-28
HUE058009T2 (en)	2022-06-28
TN2017000244A1 (en)	2018-10-19
JOP20150301B1 (en)	2023-09-17
CL2017001488A1 (en)	2018-02-23
PL3230281T3 (en)	2021-12-13
TWI780562B (en)	2022-10-11
NI201700073A (en)	2017-10-24
EP3587417A1 (en)	2020-01-01
HRP20220371T1 (en)	2022-05-13
US10472354B2 (en)	2019-11-12
NZ761161A (en)	2024-04-26
AU2015359626B2 (en)	2020-07-23
MA50674B1 (en)	2022-11-30
IL283979B (en)	2022-04-01
JP2019059742A (en)	2019-04-18
PE20180227A1 (en)	2018-01-31
EA034273B1 (en)	2020-01-23
NZ733108A (en)	2022-03-25
SV2017005461A (en)	2018-04-30
EP3587417B9 (en)	2022-03-30
US20190185466A1 (en)	2019-06-20
SI3230281T1 (en)	2021-08-31
CN107207507B (en)	2020-11-06
HRP20211002T1 (en)	2021-09-17
IL283979A (en)	2021-07-29
KR20170093203A (en)	2017-08-14
IL252665A0 (en)	2017-08-31
PL3587417T3 (en)	2022-06-13
CU24411B1 (en)	2019-05-03
EP3230281B1 (en)	2021-05-26
US10174016B2 (en)	2019-01-08
IL275183B (en)	2021-06-30
US11142523B2 (en)	2021-10-12
CN110256418B (en)	2023-01-20
ES2908822T3 (en)	2022-05-04
CY1125083T1 (en)	2023-06-09
CY1124486T1 (en)	2022-07-22
SG10202012274RA (en)	2021-01-28
EA201791261A1 (en)	2017-12-29
LT3230281T (en)	2021-07-12
IL269467A (en)	2019-11-28
US20230053411A1 (en)	2023-02-23
CN110256418A (en)	2019-09-20
SI3587417T1 (en)	2022-04-29
UY36422A (en)	2016-06-30
US20180118731A1 (en)	2018-05-03
PH12017501079A1 (en)	2017-10-18

Publication	Publication Date	Title
IL283979B (en)	2022-04-01	1,3-thiazol-2-yl substituted benzamides
GB201413037D0 (en)	2014-09-03	Beyond 10
GB201418612D0 (en)	2014-12-03	Umajin 1
GB201418846D0 (en)	2014-12-03	MicroSub 1
GB201416254D0 (en)	2014-10-29	LiftEye 2014
GB201414175D0 (en)	2014-09-24	Pris-map 1
GB201413386D0 (en)	2014-09-10	Taggstar 2
GB201413310D0 (en)	2014-09-10	Taggstar 2
GB201413313D0 (en)	2014-09-10	Kapiche 1
GB201412713D0 (en)	2014-09-03	Soundwall 2
GB201412900D0 (en)	2014-09-03	The brolly head
GB201408330D0 (en)	2014-06-25	Pckaging 32
GB201408307D0 (en)	2014-06-25	Pakaging 22
GB201406497D0 (en)	2014-05-28	Skytag 2
GB201401037D0 (en)	2014-03-05	54545
GB201418606D0 (en)	2014-12-03	Lifteye october 2014
GB201416686D0 (en)	2014-11-05	Cine 8
GB201406945D0 (en)	2014-06-04	The micro-matchbox effect
GB201404760D0 (en)	2014-04-30	Concept 85
GB201404761D0 (en)	2014-04-30	Concept 86